Delving into the Latest Updates on Vedolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Kynteles, Vedolizumab (Genetical Recombination), Vedolizumab (genetical recombination) (JAN)

+ [13]

Target

α4β7

Action

antagonists

Mechanism

α4β7 antagonists(Integrin alpha-4/beta-7 antagonists)

Therapeutic Areas

Immune System DiseasesDigestive System DisordersOther Diseases+ [2]

Active Indication

Ileal DiseasesCrohn's disease, active moderateCrohn's disease, active severe+ [9]

Inactive Indication

Acute Graft Versus Host DiseaseCeliac DiseaseCholangitis, Sclerosing+ [8]

Originator Organization

Millennium Pharmaceuticals, Inc.

Active Organization

Takeda Pharmaceutical Co., Ltd.Takeda Development Center Americas, Inc.Takeda Pharma A/S

+ [8]

Inactive Organization

Millennium Pharmaceuticals, Inc.

License Organization

Royalty Pharma PlcThe General Hospital Corp.

Drug Highest PhaseApproved

First Approval Date

United States (20 May 2014),

Colitis, UlcerativeCrohn Disease

RegulationFast Track (United States), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Login to view timeline

Structure/Sequence

Sequence Code 9976148H

Source: *****

Sequence Code 13007748L

Source: *****

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits because of bowel swelling (inflammation) are needed and has an impact on the quality of life of children and teenagers who received vedolizumab SC.
In this study, participants who responded well to the treatment with vedolizumab SC in the parent study (VedolizumabSC-3003 [NCT06100289]) will continue to be treated with vedolizumab SC. Participants who did not respond well to the treatment with vedolizumab SC in the parent study or who received corticosteroids in the last 4 weeks of the parent study will not receive vedolizumab SC in this study but will be followed for up to 2 years after the last treatment with vedolizumab SC in the parent study.
During the study, participants will visit their study clinic several times.

Start Date22 Oct 2025

Sponsor / Collaborator

Takeda Pharmaceutical Co., Ltd.

NCT06880744

/ RecruitingPhase 3

Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Na?ve to Targeted Therapies

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to severe UC who are naive to targeted therapies (TaTs).
Risankizumab and vedolizumab are approved medications for moderate to severe UC in multiple countries. Participants who meet the eligibility criteria will be randomized in a 1:1 ratio to receive open label risankizumab or vedolizumab. Approximately 530 adult participants with moderate to severe UC who are na?ve to targeted therapies (TaTs) will be enrolled at 285 sites worldwide.
For participants randomized to risankizumab, drug will be administered intravenous(IV) during the induction period followed by subcutaneous injection during the maintenance period. Participants randomized to vedolizumab will receive drug IV throughout the study.
The duration of the study is approximately 69 weeks for participants randomized to risankizumab and 71 weeks for participants randomized to vedolizumab. This includes up to a 35-day screening period followed by a treatment period of 44 weeks for risankizumab and 46 weeks for vedolizumab.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect and safety of the treatment will be checked by medical assessments, evaluation of side effects and completing questionnaires.

Start Date17 Jun 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06850727

/ RecruitingPhase 2

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

Start Date02 Jun 2025

Sponsor / Collaborator

Odyssey Therapeutics, Inc.

100 Clinical Results associated with Vedolizumab

Login to view more data

100 Translational Medicine associated with Vedolizumab

Login to view more data

100 Patents (Medical) associated with Vedolizumab

Login to view more data

2,129

Literatures (Medical) associated with Vedolizumab

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

X-linked Deficiency in ELF4 in Females with Skewed X Chromosome Inactivation

Article

Author: Zhou, Lina ; Du, Hongqiang ; Liu, Zhifeng ; Sun, Gan ; Zhang, Zhuo ; An, Yunfei ; Zhang, Qianlu ; Zhao, Rongtao ; Mei, Shiyue ; Zhao, Xiaodong ; Tang, Xuemei ; Lv, Qianying ; Zhou, Fang ; Sun, Li

Deficiency in ELF4, X-linked (DEX) is a newly identified monogenic autoinflammatory disease. Most reported cases are male, leading to the recognition of DEX being primarily limited to male patients. Here we described 3 pediatric female patients with DEX from 3 unrelated families, who are all heterozygous for ELF4 mutations (c.320_c.321insA, c.329delA and c.685 A > G). Similar to reported male DEX patients, the main clinical features include recurring oral ulcers, abdominal pain and diarrhea with colonoscopy showing ulcers in the colon. Meanwhile, novel and effective treatment strategies, such as the use of the biologic vedolizumab and exclusive enteral nutrition (EEN), have provided additional options for the treatment of DEX. Finally, we observed skewed X chromosome inactivation patterns in all three female patients, with over-inactivation of the X chromosome carrying the wild-type allele confirmed in two of them.

01 Oct 2025·IMMUNOLOGY LETTERS

Identification of S100A9 as a target for diagnosis and treatment of Crohn’s Disease after Vedolizumab treatment failure

Article

Author: Lv, Wen ; He, Yijia ; Zhang, Zhe ; Ning, Shiyang ; Xia, Yimeng ; Feng, Baisui ; Liu, Ruixian ; Sun, Qiankun ; Li, Yilong ; Zhang, Yanru ; Pang, Xinji ; Yu, Junzhi ; Liu, Lu ; Liu, Yan ; Wang, Zhihong

The vedolizumab medication is the treatment that precisely targets the gut for Crohn's Disease (CD). It can inhibit the migration of lymphocytes to the intestinal site despite the fact that a significant portion of the population continues to be ineffectively treated. In this study, peripheral blood leukocytes sampled from the CD patients who are nonresponsive or responsive to vedolizumab treatment were used for transcriptome sequencing. Intersected differentially expressed mRNA obtained from transcriptome sequencing and GSE191328 were utilized to predict key therapeutic targets. Bioinformatics analyses were used to explore potential biological mechanisms and to screen pivotal genes. Inhibitor of S100A9 increased the body weight and colon length of mice with colitis, and decreased the DAI score. Our study also demonstrated that the combination of anti-α4β7 integrin antibody with inhibitor of S100A9 further alleviates colitis. Through flow cytometry, changes in the composition of immune cell populations in colon tissues were found after intragastric administration of paquinimod, an inhibitor of S100A9. It is important that blocking S100A9 inhibited the recruitment of neutrophils in the mice's colon. Our findings lay a foundation for the further exploration of the new targets for non-responders to vedolizumab in CD patients.

01 Sep 2025·AUTOIMMUNITY REVIEWS

Combination targeted therapy with two biologic/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy

Review

Author: Sfikakis, Petros P ; Fragoulis, George E ; Gottenberg, Jacques-Eric ; Baraliakos, Xenofon ; Lignou, Angeliki Zoi ; Vassilakis, Konstantinos D

BACKGROUND:

Immune-mediated inflammatory diseases (IMID) include rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), Crohn's disease (CD), ulcerative colitis (UC), and psoriasis (PsO). While biologic (b) and targeted synthetic (ts) DMARDs are effective, nearly 60 % of patients fail to achieve low disease activity status. Combination targeted therapy (CTT) using concomitantly two different b- or ts-DMARDs has been explored, but results on safety and efficacy are unclear.

OBJECTIVE:

To systematically review the literature on CTT in IMID.

METHODS:

Following the PICO framework, we included literature of adult patients (≥18 years) with IMID receiving CTT. Three databases (PubMed, Scopus, Epistemonikos) were searched up to June 2024. Studies in non-English, pediatric populations, and non-approved treatments were excluded. Risk of bias was assessed using approved tools.

RESULTS:

Of 2038 records, 70 studies (6 RCTs, 11 cohorts, 22 case series, 31 case reports) involving 1200 patients were analyzed. About 75 % of them demonstrated low risk of bias. The most studied combinations were TNFi+IL/23i, JAKi+bDMARDs, and vedolizumab+TNFi. Approximately 40-60 % of patients with PsA, axSpA, and IBD with refractory disease improved with TNFi+IL/23i CTT. About half of patients with inflammatory arthritis and up to 80 % of IBD cases benefited with JAKi+bDMARD CTT, whereas favorable outcomes were observed in 30-50 % of IBD patients following Vedolizumab+TNFi CTT. Safety profiles were generally acceptable, without emerging signals so far.

CONCLUSION:

CTT benefits about half of refractory IMID patients, particularly TNFi/IL-23i, JAKi/bDMARD, and vedolizumab/TNFi combinations, without raising significant safety issues. Further research is needed to clarify safety and efficacy across diseases.

194

News (Medical) associated with Vedolizumab

09 Jul 2025

·www.globenewswire.com

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nutrition, and diagnostics. His expertise spans from preclinical translational medicine through Phase 1-4 clinical development. Notably, his leadership has contributed to multiple drug development programs, including two successful regulatory approvals (NDA/sBLA): infliximab for pediatric Crohn’s disease and lorcaserin for morbid obesity. Following a successful academic career as an Assistant Professor at both Duke University and the University of Pennsylvania, Dr. Chuang transitioned into the pharmaceutical industry, where he has earned a reputation for simplifying complex challenges into actionable development strategies. His work includes significant contributions to programs targeting inflammatory bowel diseases (IBD), including infliximab and vedolizumab. “We are very pleased to welcome Emil to our Board of Directors. His extensive clinical development experience and deep understanding of IBD will provide valuable insight as we continue to execute our clinical programs. We look forward to leveraging his knowledge to advance our pipeline,” commented JD Finley, Chief Executive Officer of Palisade Bio. “I am excited to work with the Palisade team to help unlock the full value of its pipeline and bring meaningful solutions to patients where there remain unmet medical needs,” added Dr. Chuang. “The progress made to date, as well as the data demonstrated by PALI-2108 for addressing Fibrostenotic Crohn’s Disease and Ulcerative Colitis is very compelling, and I look forward to helping advance these important programs.” Dr. Chuang currently serves as the Chief Medical Officer at Intrinsic Medicine, a privately held biotechnology company. He also leads Chuang Global Consulting, his independent advisory firm. His prior leadership roles include Head of GI Clinical Development for Nestlé Health Science, Head of GI Translational Research and Early Clinical at Takeda, and Head of GI Precision Medicine at Progenity. Over the course of his career, Dr. Chuang has authored more than 80 peer-reviewed publications, abstracts, and book chapters. He received his medical degree (MB BS) from the University of Sydney, Australia and completed his pediatrics specialty training (FRACP) in Australia before moving to the United States, where he completed subspecialty training in both pediatric gastroenterology and nutrition. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study and indications and anticipated benefits of PALI-2108. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the timing and success of preclinical studies and clinical trials conducted by the Company; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; the Company’s need to raise significant additional funds to continue its plans and operations; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas908-824-0775PALI@jtcir.com Attachment Figure: 1

Executive ChangeDrug Approval

10 Jun 2025

·www.fiercebiotech.com

Odyssey abandons IPO plans in latest sign of tough environment for biotech listings

Odyssey Therapeutics announced its IPO ambitions in January around the same time as Sionna Therapeutics.\n Odyssey Therapeutics has bailed on its long-awaited public listing, providing further evidence that the IPO window remains firmly shut for now.The autoimmune- and inflammatory-disease-focused biotech first announced an ambition in January to go public as part of a mini-wave of like-minded drug developers. But the company informed the Securities and Exchange Commission on Monday that it is withdrawing its registration statement because the drug developer “has determined that it is not in the best interests of the company to conduct the proposed offering at this time.”Odyssey’s decision shouldn’t come as a surprise; capital markets experts have already predicted to Fierce that the market turbulence unleashed by President Donald Trump’s tariff policies would likely evaporate the trickle of biotech IPOs that were expected in 2025.Odyssey had been eyeing an IPO as way to access fresh funding for a pipeline led by an RIPK2 inhibitor that was being readied for phase 2 trials for ulcerative colitis as a monotherapy and in combination with Takeda’s Entyvio.The biotech has previously struck deals to add to its assets and capabilities, buying Rahko for its machine learning prowess and acquiring IFM Discovery for MDA5 and NLRP1 discovery programs. IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary Glick, Ph.D. Glick previously set up and ran Scorpion Therapeutics, which Eli Lilly recently bought for up to $2.5 billion.Odyssey has also bagged Big Pharma partnerships, included receiving $6.5 million from Johnson & Johnson to jointly discover and optimize small molecules using Odyssey’s artificial intelligence and machine learning capabilities. Meanwhile, Pfizer paid $1 million as part of a collaboration intended to identify novel hits using Odyssey’s natural product platform. The biotech announced its IPO ambitions in January around the same time as Sionna Therapeutics—which did follow through with its plans to go public. Sionna raised $219.2 million via its listing in February, and the cystic fibrosis-focused biotech’s shares closed trading Monday at $16.46, slightly below their $18 debut price.Other biotechs that squeezed in through the short-lived IPO window at the start of the year include Maze Therapeutics and Metsera Therapeutics. Metsera’s stock has soared 66% from a January debut of $18 to a Monday closing price of $30 thanks in part to some impressive weight loss data yesterday.Kidney-disease-focused Maze has been less successful, with its shares trading down 20% at $12.81 yesterday compared to a debut price of $16.

IPOAcquisitionPhase 2

10 Jun 2025

·www.pharmaceutical-technology.com

Odyssey bails on public listing as US IPO landscape stutters

Nasdaq’s trading boards will not parade Odyssey Therapeutics’ name for the time being. Credit: Goran Vrhovac via Shutterstock. Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO). The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO ambitions in January 2025. While Sionna Therapeutics, a biopharma that filed IPO paperwork at the same time, went on to close a nearly $220m IPO in February, Odyssey has bailed on a public listing. Odyssey did not disclose the number of its common stock shares it was offering, nor the price at which the IPO would conduct on each share. The Form S-1, a registration form with the US Securities and Exchange Commission (SEC) for companies carrying out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Odyssey was eyeing an IPO as a way to fund its pipeline, headed by RIPK2 inhibitor OD-07656 that was set for Phase II trials for ulcerative colitis treatment, both as a monotherapy and in combination with Takeda’s blockbuster Entyvio (vedolizumab). As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. In its notice to the SEC outlining the withdrawal of the registration statement, Odyssey stated it is because it is “not in the best interests of the company to conduct the proposed offering at this time”. The IPO U-turn is the first sign that the health of the IPO landscape could be suffering in the wake of economic fallout from US President Donald Trump’s policies. Indeed, it consolidates predictions made by one GlobalData analyst earlier this year. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence In April, GlobalData business fundamentals analyst Alison Labya said: “The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence. “Additionally, Trump’s recent tariff announcement on imports from Canada, Mexico, and China has led to increased market volatility, potentially delaying IPOs as investors await the countries’ responses to the tariffs.” Biotech IPOs saw a strong recovery in 2024 , with a total raise of $8.52bn, up 68.4% from $5.06bn raised in 2023. It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and Metsera Therapeutics. U-turning on IPOs is rare, but Odyssey is not the only biotech to bail on a public listing in the past year. Australian biotech Telix Pharmaceuticals withdrew its US public listing at the last minute in June 2024, also citing unfavourable market conditions at the time. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

IPO

100 Deals associated with Vedolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08083	Vedolizumab	L04AA33	DB09033

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ileal Diseases	South Korea	Takeda Pharmaceuticals Korea Co., Ltd.	19 Jun 2015
Crohn's disease, active moderate	European Union	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Iceland	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Liechtenstein	Takeda Pharma A/S	22 May 2014
Crohn's disease, active moderate	Norway	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	European Union	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Iceland	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Liechtenstein	Takeda Pharma A/S	22 May 2014
Crohn's disease, active severe	Norway	Takeda Pharma A/S	22 May 2014
Pouchitis	European Union	Takeda Pharma A/S	22 May 2014
Pouchitis	Iceland	Takeda Pharma A/S	22 May 2014
Pouchitis	Liechtenstein	Takeda Pharma A/S	22 May 2014
Pouchitis	Norway	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	European Union	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Iceland	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Liechtenstein	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active moderate	Norway	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	European Union	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	Iceland	Takeda Pharma A/S	22 May 2014
Ulcerative colitis, active severe	Liechtenstein	Takeda Pharma A/S	22 May 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pediatric Crohn's Disease	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	China	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Japan	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Australia	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Belgium	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Canada	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Croatia	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Czechia	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Greece	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022
Pediatric Crohn's Disease	Phase 3	Hungary	Takeda Pharmaceutical Co., Ltd.	30 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02620046 (CTgov)	Phase 3	Crohn Disease \| Colitis, Ulcerative	746	Vedolizumab SC (Ulcerative Colitis: Vedolizumab 108 mg)	nfkbkdoect = ftsybwtrlv yjqzyzxpzq (zuqmvzrahd, tpzcsykixl - fjhmbhital) View more	-	03 Apr 2025
				Vedolizumab SC (Crohn's Disease: Vedolizumab 108 mg)	nfkbkdoect = bhsospatpd yjqzyzxpzq (zuqmvzrahd, dzwlmqrctl - yvuvuztfqi) View more
NCT02862132 (VEDOKIDS, Pubmed \| Lancet Gastroenterol Hepatol)	Not Applicable	Inflammatory Bowel Diseases Maintenance	137	Vedolizumab	yuerlrbqdq(sjbqvmmjfq) = vanyjskflb vnxcrwabbt (undscigxvy ) View more	Positive	01 Mar 2025
ChiCTR2200063233 (Early CD, PRNewswire) Manual	Phase 4	Crohn Disease	172	维得利珠单抗	zwyixxyfly(mqutigeukv) = onsslqsfvy kcyosqdbbw (mztfmdrlaz ) View more	Positive	21 Feb 2025
NCT04804540 (CTgov)	Phase 4	Crohn Disease \| Colitis, Ulcerative	150	Vedolizumab (UC Participants: Vedolizumab 300 mg)	urtouirdkk = yppojiligi yzqvadfdzg (stgvmjlrxk, rwqxxkisez - tairnshsjl) View more	-	12 Feb 2025
				Vedolizumab (CD Participants: Vedolizumab 300 mg)	urtouirdkk = ttwfwnguvc yzqvadfdzg (stgvmjlrxk, lddfskfexc - tasqohnpof) View more
ESMO_IO2024	Not Applicable	Colitis	74	Vedolizumab	rehpcvlshx(peznlwgebu) = xrgueifvce vgiyiaxida (pdwxnyydrz )	-	12 Dec 2024
LONG-LIVE IG-IBD (UEGW2024)	Not Applicable	-	-	Vedolizumab	exixmrqvrv(umelxashjb) = urqlusrmiq kmyoklpuzk (vawtcqmsng )	Positive	13 Oct 2024
				Vedolizumab (CD patients)	mdrdofoptk(szmgycsehf) = wangqtslvs ywuvicxzij (simmgfshsl, 1.37) View more
UEGW2024	Not Applicable	Inflammatory Bowel Diseases	-	Subcutaneous Vedolizumab (SC VDZ)	kwueieqzwo(qfcqetlkae) = Overall, 29.7 % of patients ceased SC VDZ treatment after a median of 20 (IQR 6-26) weeks. Cessation was due to secondary response losing in 3/6 and 4/5 patients in CD and UC group. In case of 2 and one patients, SC treatment was terminated due to local reactions. One patient was fear of needle. Severe adverse event did not occur. jpptcznase (bdqtnptfxb )	-	13 Oct 2024
				Intravenous Vedolizumab (IV VDZ)
UEGW2024	Not Applicable	Inflammatory Bowel Diseases	-	Subcutaneous Vedolizumab	xsciusaplh(fqegpzxyew) = torlqcfmqx dwzrzblarq (waykrzmyxx )	-	13 Oct 2024
				Intravenous Vedolizumab	xsciusaplh(fqegpzxyew) = tflygsfjgx dwzrzblarq (waykrzmyxx )
UEGW2024	Not Applicable	Colitis, Ulcerative	-	Anti-TNFs	ygvvetixrj(segsvpwfss) = 1/16 (6.3%) with no cases of herpes zoster or thrombo-embolic events nfkqdbvrwg (jgogteggsd ) View more	-	13 Oct 2024
				Ustekinumab
UEGW2024	Not Applicable	Colitis, Ulcerative	-	Vedolizumab IV infusion every 8 weeks (Q8W)	ufhmzeuoyg(bwankoucbd) = pgiwlzicmp ypjnxllzfd (gadylqztok ) View more	-	13 Oct 2024
				Vedolizumab IV infusion every 4 weeks (Q4W)	ufhmzeuoyg(bwankoucbd) = jedmtounnl ypjnxllzfd (gadylqztok ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Vedolizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation